Annual revenue of the pharmaceutical company Chiesi 2009-2023

Chiesi is one of the leading Italian pharmaceutical companies. Over the last few years, the revenue generated by Chiesi steadily increased, peaking in 2023 at over three billion euros. Correspondingly, the number of employees and the investments in research and development grew.

 Therapeutic areas

Chiesi was founded in 1935, but the process of internationalization of the brand did not start until the late 70s. In the same period, Clenil – one of the most successful products developed by this firm - was launched on the market. Clenil is used to treat issues of the respiratory system such as asthma or airway inflammation. Not surprisingly, the company is now specialized in the production of drugs for the respiratory system as well as in the manufacture of medications for primary care, neonatology and rare diseases.  

Internationalization

The internationalization activities became more intense starting from the late 80s, when the Group opened many affiliates worldwide. Currently, the importance of Chiesi on an international scale is also confirmed by its presence in the ranking of the leading Italian pharmaceutical companies in 2021.